Overview
- Columbia University researchers develop inhalable IL-12 mRNA therapy, showing promise in treating lung cancer in mice.
- The therapy uses extracellular vesicles for targeted delivery to the lungs, leading to smaller tumors and stronger immune responses.
- Inhalation method proves more efficient and less toxic than traditional delivery methods, offering a new approach to cancer treatment.
- The therapy activates the immune system, enabling it to target and destroy tumor cells more effectively.
- Human studies are necessary to confirm the therapy's effectiveness and safety in treating lung cancer.